Clinical Development - As of May 15, 2024, the Company initiated dosing of nine patients in Cohorts 1 and 2 of its Phase 1/2a study of [212Pb]VMT-α-NET, with seven patients receiving 185 MBq (5 mCi) in Cohort 2[2] - The Company is collaborating with thought leaders on investigator-initiated studies to further elucidate the clinical profile of [212Pb]VMT-α-NET[5] - The Company entered a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb]VMT01 in combination with nivolumab in patients with melanoma[15] - The company expects to submit the VMT01 study amendment in Q2 2024 and anticipates the U.S. Phase I study for PSV359 to commence in 2025[48] - The company aims to file an IND for PSV359 in late 2024, with research and development expenses expected to increase as it invests in new drug development[48] Financial Performance - Net loss for the three months ended March 31, 2024, was $12.3 million, or $0.02 loss per basic and diluted share, compared to a net loss of $0.4 million, or $0.00 per basic and diluted share, for the same period in 2023[44] - Grant revenue for the three months ended March 31, 2024, was $0.3 million, an increase of approximately 50% compared to $0.2 million for the same period in 2023[32] - Grant revenue for Q1 2024 was $325,000, an increase of 39.5% compared to $233,000 in Q1 2023[51] - The net loss from continuing operations for Q1 2024 was $11,825,000, compared to a net loss of $9,405,000 in Q1 2023, representing a 25.7% increase in losses[51] - The company reported a basic and diluted loss per share of $0.02 for Q1 2024, compared to a loss of $0.00 in Q1 2023[51] Expenses - Research and development expenses increased by approximately 127% to $7.5 million for the three months ended March 31, 2024, compared to $3.3 million for the same period in 2023[42] - Research and development expenses rose to $7,452,000 in Q1 2024, up 125% from $3,309,000 in Q1 2023[51] - Total operating expenses for the quarter ended March 31, 2024, were $13.3 million, an increase of approximately 33% compared to $10.0 million for the same period in 2023[34] - Total operating expenses increased to $13,330,000 in Q1 2024, compared to $9,994,000 in Q1 2023, reflecting a 33.3% rise[51] Cash and Assets - Cash, cash equivalents, and short-term investments as of March 31, 2024, were $180.6 million, compared to $9.2 million on December 31, 2023[45] - Cash, cash equivalents, and short-term investments increased significantly to $180,648,000 as of March 31, 2024, from $9,238,000 as of December 31, 2023[55] - Total assets grew to $278,286,000 as of March 31, 2024, compared to $97,891,000 at the end of 2023[55] Strategic Developments - The Company closed the acquisition of a state-of-the-art radiopharmaceutical manufacturing facility in Somerset, New Jersey, with filing expected in the second half of 2024[29] - The company is developing a proprietary 212Pb generator to secure key isotopes for clinical trials and commercial operations[52] - The Company raised $177.2 million in gross proceeds through various financing transactions and an additional $49.5 million subsequent to March 31, 2024, under its ATM Agreement[9]

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annual Healthrup ...

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annual Healthru ...

Table of Contents Expand the potential of its program candidates in additional indications and as combination therapies in current and additional indications. SSTR2, the molecular target of [212Pb]VMT-α-NET, is overexpressed in a number of cancers that are not classified as NETs, including meningioma and neuroblastoma. Both of these cancers can be difficult to treat when advanced and inoperable, but this is especially true for advanced neuroblastoma, a rare and orphan pediatric disease that is one of the mo ...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE – March 28, 2024 – Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. "We made tremendous progress during 2023 in building a fully integrated radiopharmaceu ...

SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Previously operated by Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LN ...

SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select group of institutional accredited investors, to sell securities in a private placement for aggregate gross proceeds of approximately $87.4 million, before deducting placement agent fees and other of ...

SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024. Fireside Chat with JonesResearch – February 28, virtualTime: 11 a.m. ETParticipant: Michael K. Schultz, Ph.D., Chief Science OfficerPlease RSVP to your ...

Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant to Develop Differentiated Antibody-based Radiopharmaceutical Approach SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) --  -- Perspective Therapeutics, Inc.  ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has executed an exclusi ...

SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the closing of its previously announced underwritten public offering of (i) 156,399,542 shares of its common stock at the public offering price of $0.37 per share, including the exercise in full by the underwriters of their option to purchase up to an additional ...